Prognostic value of plasma fibroblast growth factor 21 among patients with acute ischemic stroke
暂无分享,去创建一个
Jiang He | D. Geng | C. Zhong | Hao Peng | Aili Wang | Tan Xu | Yonghong Zhang | Z. Ju | Zhengbao Zhu | Xiaowei Zheng | Yanbo Peng | D. Guo
[1] Ming Liu,et al. Stroke in China: advances and challenges in epidemiology, prevention, and management , 2019, The Lancet Neurology.
[2] Feng Liu,et al. Erratum. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes 2008;57:1246–1253 , 2018, Diabetes.
[3] A. Suksamrarn,et al. Dihydrocapsaicin Attenuates Blood Brain Barrier and Cerebral Damage in Focal Cerebral Ischemia/Reperfusion via Oxidative Stress and Inflammatory , 2017, Scientific Reports.
[4] Y. Asano,et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease , 2017, PloS one.
[5] F. Gómez-Pérez,et al. Fibroblast growth factor 21 and its novel association with oxidative stress , 2016, Redox biology.
[6] D. Chuang,et al. Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation , 2016, Scientific Reports.
[7] A. Keech,et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study , 2015, Diabetologia.
[8] J. Chen,et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. , 2014, JAMA.
[9] Andrew E Moran,et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet. Global health.
[10] B. Cheung,et al. Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[11] A. Nowakowski,et al. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. , 2013, Diabetes research and clinical practice.
[12] Xiu-Ling Deng,et al. Oxidative stress impairs IKCa- and SKCa-mediated vasodilatation in mesenteric arteries from diabetic rats. , 2013, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[13] L. Ferrucci,et al. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults , 2013, Journal of Human Hypertension.
[14] Ji A. Seo,et al. Fibroblast Growth Factor 21: A Novel Metabolic Regulator , 2012, Diabetes & metabolism journal.
[15] Liping Liu,et al. Stroke and stroke care in China: huge burden, significant workload, and a national priority. , 2011, Stroke.
[16] Hao Li,et al. Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR) , 2011, Stroke.
[17] Jian Xiao,et al. Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile , 2010, PloS one.
[18] J. Flier,et al. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.
[19] C. Allen,et al. Oxidative Stress and Its Role in the Pathogenesis of Ischaemic Stroke , 2009, International journal of stroke : official journal of the International Stroke Society.
[20] J. Flier,et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. , 2009, Endocrinology.
[21] M. Matoulek,et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.
[22] R. DeFronzo,et al. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.
[23] K. Xiang,et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. , 2009, The Journal of clinical endocrinology and metabolism.
[24] D. Moller,et al. Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.
[25] Feng Liu,et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.
[26] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[27] P. Dorman,et al. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies , 2008, BMJ : British Medical Journal.
[28] J. Flier,et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.
[29] Yun-Fei Chen,et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.
[30] J. Gromada,et al. FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.
[31] T. Kurtz,et al. Recommendations for blood pressure measurement in animals: summary of an AHA scientific statement from the Council on High Blood Pressure Research, Professional and Public Education Subcommittee. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[32] Jun Yang,et al. Proportion of different subtypes of stroke in China. , 2003, Stroke.
[33] R. Simon,et al. Flexible regression models with cubic splines. , 1989, Statistics in medicine.
[34] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.